Visualitzant O - Articles científics per títol

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies

Lazar, Vladimir; Girard, Nicolas; Raymond, Eric; Martini, Jean-François; Galbraith, Susan; Raynaud, Jacques; Felip Font, Enriqueta; Tabernero Caturla, Josep (American Society of Clinical Oncology, 2022-09-15)

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies

León-Román, Juan; Bolufer Cardona, Monica; Sánchez-Salinas, Mario; Alonso-Martínez, Carla; Bestard, Oriol; IACOBONI, GLORIA; Bermejo García, Sheila; Cecilia del Carmen, Carpio Segura; Garcia-Carro, Clara; Barba, Pere; Soler, María José (Oxford University Press, 2024-03)

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Jerusalem, Guy; Park, Yeon Hee; Yamashita, Toshinari; Hurvitz, Sara; Modi, Shanu; André, Fabrice; Saura Manich, Cristina (American Association for Cancer Research, 2022-12-01)

Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)

Modi, Shanu; Krop, Ian; Park, Yeon Hee; Kim, Sung‑Bae; Tamura, K.; Saura Manich, Cristina (Elsevier, 2024-03)

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

López-Miranda, Elena; Perez-Garcia, Jose Manuel; Brain, Etienne; Ravnik, Maja; Escriva de Romaní Muñoz, Santiago Ignacio; Cortés Castan, Javier; Di Cosimo, Serena (MDPI, 2020-11-25)

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus

Isla, Dolores; de Castro Carpeno, Javier; Garcia‑Campelo, Rosario; Lianes, Pilar; Felip Font, Enriqueta; Garrido, Pilar (Springer, 2020-05)

Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe

taieb, julien; Seufferlein, Thomas; Reni, Michele; Palmer, Daniel H.; Cubillo, Antonio; Bridgewater, John; Macarulla, Teresa (BMC, 2023-09-18)

Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort

Webb, Adam J.; Harper, Emily; Rattay, Tim; Aguado-Barrera, Miguel E.; Bourgier, Celine; Gutierrez Enriquez, Sara; Seoane Ramallo, Alejandro; Reyes López, Victoria; Azria, David (Elsevier, 2022-10)

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study

Bordonaro, R.; Calvo, A.; Auriemma, A.; Hollebecque, Antoine; Rubovszky, G.; Saunders, M. P.; Argilés Martinez, Guillem; Tabernero Caturla, Josep (Elsevier, 2021-10)

Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design

Tabernero Caturla, Josep; Prager, Gerald W; Leger, Catherine; Fakih, Marwan; Taieb, Julien; Ciardiello, Fortunato (Future Medicine, 2021-06)

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

Van Cutsem, Eric; Danielewicz, I.; Saunders, M. P.; Pfeiffer, P.; Argilés Martinez, Guillem; Borg, Christophe (Elsevier, 2020-09)

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

Tabernero Caturla, Josep; Shitara, Kohei; Zaanan, Aziz; Doi, Toshihiko; Lorenzen, S.; Van Cutsem, Eric; Alsina Maqueda, Maria (Elsevier, 2021-08)

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

Napolitano, Stefania; Matrone, Nunzia; Muddassir, A. L.; Martini, Giulia; Sorokin, A.; De Falco, Vincenzo (BMC, 2019-12-16)

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer

Tolaney, Sara M; Arteaga, Carlos; Cortés Castan, Javier; Sohn, Joohyuk; Rugo, Hope; Bardia, Aditya (Future Medicine, 2020-04)

TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC

Levy, Benjamin; Cappuzzo, Federico; Yoneshima, Yasuto; Reck, Martin; Yang, James Chih-Hsin; FELIP, ENRIQUETA (Future Medicine, 2023-07)

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

Vieito Villar, Maria; De Vos, Filip; Marjolein Geurts; Lorenzi, Elena; Moreno, Victor; Simonelli, Matteo (Oxford University Press, 2022-01)

TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors

Nagasaka, Misako; Ohe, Yuichiro; Choi, Chang-Min; Yang, Nong; FELIP, ENRIQUETA; Zhou, Caicun; Liu, Geoffrey (Future Medicine, 2023-01)

Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation

Rofes, Paula; Duenas Cid, Nuria; del Valle, Jesús; Navarro, Matilde; Balmaña, Judith; Ramon y Cajal, Teresa (Wiley, 2024-04-01)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

Casarrubios García, Marta; Garcia‑Campelo, Rosario; Martínez Marti, Alexandre; Insa, Amelia; Provencio, Mariano; Nadal, Ernest; Lázaro, Martín (BMJ, 2022-09)

Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment

Vergote, Ignace; Hirsch, Fred R.; Hagemann, Carsten; Miller, David; Macarulla, Teresa (MDPI, 2023-01-19)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus

Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe

Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study

Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer

TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors

Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies ﻿

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies ﻿

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis ﻿

Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01) ﻿

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial ﻿

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus ﻿

Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe ﻿

Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort ﻿

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study ﻿

Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design ﻿

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study ﻿

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study ﻿

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression ﻿

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer ﻿

TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC ﻿

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma ﻿

TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors ﻿

Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation ﻿

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy ﻿

Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus

Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe

Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study

Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression

TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer

TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma

TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors

Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment